Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Tannapfel, A., Reinacher-Schick, A., Quidde, J., Trarbach, T., Hinke, A., Schmoll, H.-J., Arnold, D., 2015.

Lancet Oncol. 16, 1355–1369. doi:10.1016/S1470-2045(15)00042-X